Compare Flagstar Bank NA (FLG) vs Novavax Inc (NVAX) Price & Performance

Flagstar Bank (FLG) trades at $11.32, showing modest daily gains of 0.18%. The stock faces bearish technical signals with all moving averages indicating selling pressure, though oscillators are neutral. Fundamentally, the company reported a Q2 2026 earnings miss but maintains profitability with a net income margin of 2.3%. Recent developments include a strategic core banking partnership with Fiserv and a $250 million share repurchase program announced in July 2026.

Analyst consensus remains bullish with a $17.07 price target (60% buy ratings), suggesting significant upside potential. However, risks include recent earnings volatility, high P/E ratio of 378, and negative operating cash flow in 2025. The stock trades below book value (P/B 0.62), offering value opportunity if operational improvements continue.

Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and strong analyst support (73.9% buy ratings). The company reported revenue of $1.12B in 2025 with a net income of $440.3M, marking a significant turnaround from prior losses, though 2026 projections show a return to negative net income. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.

The outlook is mixed: strong valuation ratios (P/E of 3.14, EV/EBITDA of 1.72) and recent earnings beats suggest undervaluation, but persistent cash burn and negative equity pose risks. Investment opportunity lies in partnership-driven growth, while risks include execution challenges and reliance on vaccine demand. Wall Street sentiment remains optimistic despite fundamental volatility.